Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
The Lancet. Oncology 2015 Jun 16 (6): 686-94.
Konecny Gottfried E, Finkler Neil, Garcia Agustin A, Lorusso Domenica, Lee Paula S, Rocconi Rodney P, Fong Peter C, Squires Matt, Mishra Kaushal, Upalawanna Allison, Wang Yongyu, Kristeleit Rebec
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015 May 26 (5): 914-20.
Monk B J, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita A S, Nieto A, Park Y C, Cheng P S, Li W, Favis R, Ricci D, Poveda